Hem › Metastaserande cancer › Virginia › Richmond
Kliniska studier för Metastaserande cancer i Richmond, VA
12 studier för Metastaserande cancer söker deltagare vid platser i och runt Richmond (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekryterarFas 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RekryterarFas 3
- Virginia Cancer Institute, Richmond
- Virginia Cancer Institute, Richmond
- Virginia Cancer Institute, Mechanicsville · 6 mi bort
- och 2 fler
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RekryterarFas 3
- Research Site, Midlothian · 11 mi bort
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
RekryterarFas 3
- Research Site, Midlothian · 11 mi bort
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekryterarFas 3
- VCU Health Adult Outpatient Pavillion, Richmond
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
RekryterarFas 2
- VCU Massey Comprehensive Cancer Center, Richmond
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RekryterarFas 2
- Virginia Commonwealth University Massey Cancer Center, Richmond
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RekryterarFas 3
- Research Site, Richmond
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
RekryterarFas 3
- Bon Secours St. Francis Medical Oncology Center, Midlothian · 11 mi bort
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
RekryterarFas 2/3
- Virginia Commonwealth University, Richmond
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RekryterarFas 3
- VCU Massey Cancer Center, Richmond
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RekryterarFas 2/3
- Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond
Metastaserande cancer-studier i andra städer
- Houston, TX104 studier
- New York City, NY93 studier
- Nashville, TN70 studier
- Boston, MA63 studier
- Los Angeles, CA57 studier
- St. Louis, MO54 studier
- Arlington, VA53 studier
- Philadelphia, PA46 studier
- Chicago, IL45 studier
- San Antonio, TX44 studier
- Washington, DC43 studier
- Dallas, TX42 studier
Andra studier i Richmond
- Bröstcancer26 studier
- Icke-småcellig lungcancer25 studier
- Prostatacancer19 studier
- Hjärtsvikt16 studier
- Lungcancer14 studier
- Hjärt-kärlsjukdom13 studier
- Kolorektal cancer13 studier
- Steatotisk leversjukdom12 studier
- Akut myeloid leukemi12 studier
- Plattenepitelcancer i huvud och hals12 studier
- Melanom11 studier
- Övervikt11 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.